Study design, patient selection, and treatment
SECONDARY, HEAD AND NECK CANCER
Our presented data were prospectively obtained as part of the so-called HEADNUT trial (head and neck cancer patients under [chemo]radiotherapy undergoing nutritional intervention; Clinical Trials Register: DRKS00016862) at the University Medical Center Hamburg-Eppendorf, Germany, between 2018 and 2022. This trial was approved by the local ethics committee (PV5818) and written informed consent was signed by all patients before study entry. Detailed information on study design, patient and primary and secondary endpoint selection have already been published elsewhere [IMRT was administered with single fractions of 1.7–2.0 Gy, 5 times/week, to total doses varying from 60–70.4 Gy alone or as combined CRT with mainly cisplatin (100 mg/m